Literature DB >> 19029326

In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.

Sachin S Bhagwat1, Pamela McGhee, Klaudia Kosowska-Shick, Mahesh V Patel, Peter C Appelbaum.   

Abstract

WCK 771 demonstrated MIC(50) and MIC(90)s of 0.03 and 1 microg/ml, respectively, against 297 recent U.S. community-acquired and hospital strains of Staphylococcus aureus, irrespective of quinolone or glycopeptide resistance. Against quinolone-resistant strains, MIC(90)s of WCK 771 and moxifloxacin were 1 and 16 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19029326      PMCID： PMC2630593          DOI： 10.1128/AAC.01150-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Authors:  Benjamin P Howden; Peter B Ward; Patrick G P Charles; Tony M Korman; Andrew Fuller; Philipp du Cros; Elizabeth A Grabsch; Sally A Roberts; Jenny Robson; Kerry Read; Narin Bak; James Hurley; Paul D R Johnson; Arthur J Morris; Barrie C Mayall; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

2.  Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus.

Authors:  Nottasorn Plipat; Gilat Livni; Heidi Bertram; Richard B Thomson
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

3.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Authors:  G Lina; Y Piémont; F Godail-Gamot; M Bes; M O Peter; V Gauduchon; F Vandenesch; J Etienne
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

5.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  In vitro activity of the new quinolone WCK 771 against staphylococci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noel J De Souza; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.

Authors:  L Ferrero; B Cameron; B Manse; D Lagneaux; J Crouzet; A Famechon; F Blanche
Journal:  Mol Microbiol       Date:  1994-08       Impact factor: 3.501

8.  In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.

Authors:  Tsuyoshi Otani; Mayumi Tanaka; Emi Ito; Yuichi Kurosaka; Yoichi Murakami; Kiyomi Onodera; Takaaki Akasaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

Authors:  Michael J Rybak; Steve N Leonard; Kerri L Rossi; Chrissy M Cheung; Helio S Sader; Helio S Sadar; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2008-07-16       Impact factor: 5.948

10.  In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor.

Authors:  R K Flamm; C Vojtko; D T Chu; Q Li; J Beyer; D Hensey; N Ramer; J J Clement; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191
View more
  15 in total

1.  In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.

Authors:  Brian J Morrow; Wenping He; Karen M Amsler; Barbara D Foleno; Mark J Macielag; A Simon Lynch; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model.

Authors:  Sachin S Bhagwat; Hariharan Periasamy; Swapna S Takalkar; Rajesh Chavan; Pavan Tayde; Amol Kulkarni; Jaikumar Satav; Vineet Zope; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.

Authors:  Jeffrey Fernandez; Jamese J Hilliard; Brian J Morrow; John L Melton; Robert K Flamm; Alfred M Barron; A Simon Lynch
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

5.  Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; Rakesh Chugh; Mugdha Gupta; Ravindra Yeole; Anasuya Patel; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 6.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

7.  Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.

Authors:  Anasuya Patel; Ganesh V Sangle; Jinal Trivedi; Sushant A Shengule; Deepak Thorve; Mohan Patil; Nitin J Deshmukh; Bhushan Choudhari; Avinash Karade; Sangita Gupta; Sachin Bhagwat; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

8.  In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.

Authors:  Y López; M Tato; P Espinal; F Garcia-Alonso; D Gargallo-Viola; R Cantón; J Vila
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

9.  In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.

Authors:  G Xue; D M Crabb; L Xiao; Y Liu; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 10.  Pipeline of Known Chemical Classes of Antibiotics.

Authors:  Cristina d'Urso de Souza Mendes; Adelaide Maria de Souza Antunes
Journal:  Antibiotics (Basel)       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.